



*SPECIFICATION AMENDMENTS*

Please replace paragraph [0009] with the following:



**[0009]** The present invention provides purine nucleoside compounds which are selective to A<sub>3</sub> adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The present invention provides compounds shown by the following general formula (I):



and isomers thereof, wherein X is sulfur or oxygen; R<sub>1</sub> is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R<sub>2</sub> is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R<sub>3</sub> and R<sub>3</sub>' are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocarbonyl, whereas R<sub>3</sub> and R<sub>3</sub>' do not have identical substituents simultaneously; and R<sub>4</sub> is hydrogen or alkyl.

Please replace paragraph [0010] with the following:


**[0010]** The foregoing need has been fulfilled to a great extent by the present invention that provides purine nucleosides selective to A<sub>3</sub> adenosine receptors. Thus, in an embodiment, the present invention provides a compound of formula (I):




wherein X is sulfur or oxygen; R<sub>1</sub> is hydrogen, C<sub>1</sub>-C<sub>5</sub> alkyl, benzyl, halobenzyl, or phenyl C<sub>1</sub>-C<sub>5</sub> alkyl; R<sub>2</sub> is hydrogen, halogen, C<sub>1</sub>-C<sub>5</sub> alkoxy group, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>5</sub> alkylthio, or thio; R<sub>3</sub> and R<sub>3</sub>' may be the same or different and are hydrogen, hydroxy C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy carbonyl, or C<sub>1</sub>-C<sub>5</sub> alkylaminocarbonyl; R<sub>4</sub> is hydrogen or C<sub>1</sub>-C<sub>5</sub> alkyl; or a pharmaceutically acceptable salt, or isomer thereof. In an embodiment, R<sub>3</sub> and R<sub>3</sub>' are not the same. In a preferred embodiment, X is sulfur.

Please replace the Abstract with the following:

Disclosed are purine nucleoside compounds that are selective to A<sub>3</sub> adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof:





wherein X is sulfur or oxygen;  $\text{R}_1$  is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl;  $\text{R}_2$  is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio;  $\text{R}_3$  and  $\text{R}_3'$  are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocarbonyl, whereas  $\text{R}_3$  and  $\text{R}_3'$  do not have identical substituents simultaneously; and  $\text{R}_4$  is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a method for preventing or treating various diseases, state, or condition, including asthma, inflammation, cerebral ischemia, heart diseases, and cancer.